Validation of the predictive value of BDNF -87 methylation for antidepressant treatment success in severely depressed patients—a randomized rater-blinded trial
Trials · 2024
DOI: 10.1186/s13063-024-08061-5 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Trials, 2024. Verfasst von Hannah Benedictine Maier und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover, 30625, Germany. Maier.Hannah@…. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Major Depressive Disorder. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, Medizinische Hochschule Hannover (MHH).
Abstract (Originalsprache)
Background
Brain-derived neurotrophic factor (BDNF) is essential for antidepressant treatment of major depressive disorder (MDD). Our repeated studies suggest that DNA methylation of a specific CpG site in the promoter region of exon IV of the BDNF gene (CpG -87) might be predictive of the efficacy of monoaminergic antidepressants such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and others. This trial aims to evaluate whether knowing the biomarker is non-inferior to treatment-as-usual (TAU) regarding remission rates while exhibiting significantly fewer adverse events (AE).
Methods
The BDNF trial is a prospective, randomized, rater-blinded diagnostic study conducted at five university hospitals in Germany. The study’s main hypothesis is that {1} knowing the methylation status of CpG -87 is non-inferior to not knowing it with respect to the remission rate while it significantly reduces the AE rate in patients experiencing at least one AE. The baseline assessment will occur upon hospitalization and a follow-up assessment on day 49 (± 3). A telephone follow-up will be conducted on day 70 (± 3). A total of 256 patients will be recruited, and methylation will be evaluated in all participants. They will be randomly assigned to either the marker or the TAU group. In the marker group, the methylation results will be shared with both the patient and their treating physician. In the TAU group, neither the patients nor their treating physicians will receive the marker status. The primary endpoints include the rate of patients achieving remission on day 49 (± 3), defined as a score of ≤ 10 on the Hamilton Depression Rating Scale (HDRS-24), and the occurrence of AE. Ethics and dissemination The trial protocol has received approval from the Institutional Review Boards at the five participating universities. This trial holds significance in generating valuable data on a predictive biomarker for antidepressant treatment in patients with MDD. The findings will be shared with study participants, disseminated through professional society meetings, and published in peer-reviewed journals.
Trial registration
German Clinical Trial Register DRKS00032503. Registered on 17 August 2023.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover, 30625, Germany. Maier.Hannah@mh-hannover.de.
- Department of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover, 30625, Germany.
- Department of Psychiatry and Psychotherapy, Otto von Guericke University Magdeburg (OVGU), Magdeburg, Germany.
- Institute of Biostatistics, Hannover Medical School, Hannover, Germany.
- Center for Clinial Trials (ZKS), Hannover Medical School, Hannover, Germany.
- Department of Psychiatry and Psychotherapy, University Hospital Schleswig Holstein, Kiel, Germany.
Förderung
- Bundesministerium für Bildung und Forschung
- Medizinische Hochschule Hannover (MHH)
Zitieren
APA
Maier, H. B., Neyazi, A., Bundies, G. L., Meyer-Bockenkamp, F., Bleich, S., Pathak, H., Ziert, Y., Neuhaus, B., Müller, F. J., Pollmann, I., Illig, T., Mücke, S., Müller, M., Möller, B. K., Oeltze-Jafra, S., Kacprowski, T., Voges, J., Müntefering, F., Scheiber, J., …, & Frieling, H. (2024). Validation of the predictive value of BDNF -87 methylation for antidepressant treatment success in severely depressed patients—a randomized rater-blinded trial. Trials. https://doi.org/10.1186/s13063-024-08061-5
Vancouver
Maier HB, Neyazi A, Bundies GL, Meyer-Bockenkamp F, Bleich S, Pathak H, et al. Validation of the predictive value of BDNF -87 methylation for antidepressant treatment success in severely depressed patients—a randomized rater-blinded trial. Trials. 2024. doi:10.1186/s13063-024-08061-5
BibTeX
@article{Maier2024,
author = {Maier, Hannah Benedictine and Neyazi, Alexandra and Bundies, Gabriel L and Meyer-Bockenkamp, Fiona and Bleich, Stefan and Pathak, Hansi and Ziert, Yvonne and Neuhaus, Barbara and Müller, Franz-Josef and Pollmann, Iris and Illig, Thomas and Mücke, Stefanie and Müller, Meike and Möller, Brinja Kira and Oeltze-Jafra, Steffen and Kacprowski, Tim and Voges, Jan and Müntefering, Fabian and Scheiber, Josef and Reif, Andreas and Aichholzer, Mareike and Reif-Leonhard, Christine and Schmidt-Kassow, Maren and Hegerl, Ulrich and Reich, Hanna and Unterecker, Stefan and Weber, Heike and Deckert, Jürgen and Bössel-Debbert, Nicole and Grabe, Hans J and Lucht, Michael and Frieling, Helge},
title = {Validation of the predictive value of BDNF -87 methylation for antidepressant treatment success in severely depressed patients—a randomized rater-blinded trial},
journal = {Trials},
year = {2024},
doi = {10.1186/s13063-024-08061-5}
}
EUVIMED